Mukhopadhyay T et al., 2002-09: The founding preclinical paper of the mebendazole-cancer literature: mebendazole caused G2-M arrest and apoptosis in human lung cancer lines, inhibited xenograft growth in nude mice when given orally, and reduced metastasis and vessel density. It is the study later cited as the start of the repurposing field.
We have found that mebendazole (MZ), a derivative of benzimidazole, induces a dose- and time-dependent apoptotic response in human lung cancer cell lines. In this study, MZ arrested cells at the G(2)-M phase before the onset of apoptosis
abstract
Mukhopadhyay T et al., 2002-09: The founding preclinical paper of the mebendazole-cancer literature: mebendazole caused G2-M arrest and apoptosis in human lung cancer lines, inhibited xenograft growth in nude mice when given orally, and reduced metastasis and vessel density. It is the study later cited as the start of the repurposing field. Study type: cell-line and mouse xenograft study (preclinical). N: multiple human NSCLC lines plus nude mouse xenografts; exact animal numbers in the full text (not read – paywalled, abstract only). Country: United States (M. D. Anderson Cancer Center, Houston, TX). Dose/route/schedule: 'administered p.o. to nu/nu mice' – the abstract gives no mg/kg figure; dose is in the full text. Funder: not stated in the abstract. Conflicts: not stated in the abstract. Product/manufacturer: not named in the abstract (laboratory-grade mebendazole). Comparator: untreated control mice; normal WI38 fibroblasts and HUVEC used as toxicity controls. Confidence HIGH for the abstract text as published on PubMed; the funding/disclosure sections live in the paywalled full text and were not verified. Also filed as MBB-13 (claims C2, C7). Study type: animal.
